Skip to main content

Compare Stocks

Date Range: 

 Autolus TherapeuticsEiger BioPharmaceuticalsCASI PharmaceuticalsCabaletta BioSurface Oncology
SymbolNASDAQ:AUTLNASDAQ:EIGRNASDAQ:CASINASDAQ:CABANASDAQ:SURF
Price Information
Current Price$6.48$8.02$1.59$10.23$8.96
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.21.81.71.61.4
Analysis Score3.43.53.53.53.4
Community Score2.42.92.52.62.6
Dividend Score0.00.00.00.00.0
Ownership Score0.02.51.71.70.8
Earnings & Valuation Score0.00.00.60.00.0
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$21.00$25.50$4.20$21.00$14.17
% Upside from Price Target224.07% upside217.96% upside164.15% upside105.28% upside58.11% upside
Trade Information
Market Cap$339.20 million$272.29 million$222.28 million$255.01 million$389.12 million
Beta1.751.540.411.672.09
Average Volume937,448247,4931,460,026108,7831,486,781
Sales & Book Value
Annual Revenue$2.91 millionN/A$4.13 millionN/A$15.36 million
Price / Sales116.56N/A53.82N/A25.33
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$5.67 per share$2.31 per share$0.76 per share$5.76 per share$2.03 per share
Price / Book1.14N/A2.09N/A4.41
Profitability
Net Income$-123,850,000.00$-70,250,000.00$-46,030,000.00$-16,940,000.00$-54,790,000.00
EPS($2.88)($3.08)($0.42)($4.07)($1.97)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-8,652.90%N/A-402.87%N/AN/A
Return on Equity (ROE)-54.01%-100.60%-60.96%-22.99%-29.77%
Return on Assets (ROA)-44.19%-57.76%-42.48%-22.38%-17.05%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A0.27%N/AN/A0.17%
Current Ratio7.43%6.23%14.99%27.95%7.94%
Quick Ratio7.43%6.23%14.86%27.95%7.94%
Ownership Information
Institutional Ownership Percentage22.86%68.77%31.95%68.00%51.97%
Insider Ownership PercentageN/A5.80%24.75%6.51%35.00%
Miscellaneous
Employees376311443351
Shares Outstanding52.35 million33.95 million139.80 million24.93 million43.43 million
Next Earnings Date8/5/2021 (Estimated)8/5/2021 (Estimated)8/9/2021 (Estimated)8/5/2021 (Estimated)8/10/2021 (Estimated)
OptionableNot OptionableNot OptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
Implied Volatility Surging for Surface Oncology (SURF) Stock OptionsImplied Volatility Surging for Surface Oncology (SURF) Stock Options
finance.yahoo.com - May 18 at 1:59 PM
Surface Oncology, Inc. (NASDAQ:SURF): The Stock To Bet On For Economic Progress In The Months AheadSurface Oncology, Inc. (NASDAQ:SURF): The Stock To Bet On For Economic Progress In The Months Ahead
marketingsentinel.com - May 18 at 8:59 AM
Surface Oncology (NASDAQ:SURF) Coverage Initiated at BTIG ResearchSurface Oncology (NASDAQ:SURF) Coverage Initiated at BTIG Research
americanbankingnews.com - May 17 at 6:08 PM
Surface Oncology, Inc. (NASDAQ:SURF)’s Stock Price Continues to FallSurface Oncology, Inc. (NASDAQ:SURF)’s Stock Price Continues to Fall
stocksregister.com - May 17 at 1:47 PM
Could Surface Oncology Be a Millionaire-Maker Stock?Could Surface Oncology Be a Millionaire-Maker Stock?
finance.yahoo.com - May 16 at 9:01 AM
Surface Oncology, Inc. (NASDAQ:SURF) Receives Average Rating of "Hold" from BrokeragesSurface Oncology, Inc. (NASDAQ:SURF) Receives Average Rating of "Hold" from Brokerages
americanbankingnews.com - May 11 at 5:28 AM
Zacks: Analysts Anticipate Surface Oncology, Inc. (NASDAQ:SURF) to Post -$0.38 EPSZacks: Analysts Anticipate Surface Oncology, Inc. (NASDAQ:SURF) to Post -$0.38 EPS
americanbankingnews.com - May 10 at 9:22 AM
Surface Oncology (NASDAQ:SURF) Posts  Earnings Results, Beats Estimates By $0.02 EPSSurface Oncology (NASDAQ:SURF) Posts Earnings Results, Beats Estimates By $0.02 EPS
americanbankingnews.com - May 6 at 9:48 PM
H.C. Wainwright Keeps Their Buy Rating on Surface Oncology (SURF)H.C. Wainwright Keeps Their Buy Rating on Surface Oncology (SURF)
smarteranalyst.com - May 6 at 2:33 PM
Surface Oncology Q1 EPS $(0.37) Down From $0.74 YoYSurface Oncology Q1 EPS $(0.37) Down From $0.74 YoY
benzinga.com - May 5 at 8:54 AM
Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2021Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2021
finance.yahoo.com - May 5 at 8:54 AM
Stock Traders Purchase High Volume of Call Options on Surface Oncology (NASDAQ:SURF)Stock Traders Purchase High Volume of Call Options on Surface Oncology (NASDAQ:SURF)
americanbankingnews.com - May 4 at 6:56 AM
BRIEF-Surface Oncology Says Co Entered Into An Exclusive Product License Agreement With Vaccinex, Inc.BRIEF-Surface Oncology Says Co Entered Into An Exclusive Product License Agreement With Vaccinex, Inc.
msn.com - May 3 at 2:00 PM
What Will Surface Oncology, Inc. (NASDAQ:SURF) Be Like After It Drops -96.99% From Its Highs?What Will Surface Oncology, Inc. (NASDAQ:SURF) Be Like After It Drops -96.99% From Its Highs?
marketingsentinel.com - May 1 at 2:48 PM
Short Interest in Surface Oncology, Inc. (NASDAQ:SURF) Rises By 55.0%Short Interest in Surface Oncology, Inc. (NASDAQ:SURF) Rises By 55.0%
americanbankingnews.com - May 1 at 5:46 AM
Surface OncologySurface Oncology
seekingalpha.com - April 30 at 3:39 AM
Surface Oncology to Present Clinical Updates for SRF388 and SRF617Surface Oncology to Present Clinical Updates for SRF388 and SRF617
finance.yahoo.com - April 28 at 8:37 PM
Surface Oncology, Inc. (NASDAQ:SURF): A Disaster In The Making Or A Gold Mine?Surface Oncology, Inc. (NASDAQ:SURF): A Disaster In The Making Or A Gold Mine?
marketingsentinel.com - April 27 at 1:19 PM
Surface Oncology Expands Leadership Team with Key Executive Appointment and PromotionsSurface Oncology Expands Leadership Team with Key Executive Appointment and Promotions
ca.finance.yahoo.com - April 27 at 8:19 AM
Surface Oncology Expands Leadership Team with  Key Executive Appointment and PromotionsSurface Oncology Expands Leadership Team with Key Executive Appointment and Promotions
finance.yahoo.com - April 27 at 8:19 AM
Reviewing BiondVax Pharmaceuticals (NASDAQ:BVXV) and Surface Oncology (NASDAQ:SURF)Reviewing BiondVax Pharmaceuticals (NASDAQ:BVXV) and Surface Oncology (NASDAQ:SURF)
americanbankingnews.com - April 26 at 4:26 AM
A Desire to Be a Healer Drives Breast Cancer Expert ForwardA Desire to Be a Healer Drives Breast Cancer Expert Forward
onclive.com - April 25 at 1:03 AM
Surface Oncology, Inc. (NASDAQ:SURF) Could Soar to Much Higher Prices in Coming MonthsSurface Oncology, Inc. (NASDAQ:SURF) Could Soar to Much Higher Prices in Coming Months
marketingsentinel.com - April 19 at 1:52 PM
Surface Oncology Named a 2021 Best Places to Work Company by Boston Business JournalSurface Oncology Named a 2021 Best Places to Work Company by Boston Business Journal
finance.yahoo.com - April 19 at 8:52 AM
Is Surface Oncology, Inc.(NASDAQ:SURF) A Great Stock To Invest In?Is Surface Oncology, Inc.(NASDAQ:SURF) A Great Stock To Invest In?
stocksregister.com - April 13 at 10:26 AM
DateCompanyBrokerageAction
5/12/2021Autolus TherapeuticsNeedham & Company LLCLower Price Target
3/16/2021Autolus TherapeuticsRedburn PartnersReiterated Rating
1/29/2021Autolus TherapeuticsJPMorgan Chase & Co.Downgrade
1/7/2021Autolus TherapeuticsTruistLower Price Target
1/7/2021Autolus TherapeuticsHC WainwrightLower Price Target
1/6/2021Autolus TherapeuticsMizuhoReiterated Rating
9/23/2020Autolus TherapeuticsWilliam BlairReiterated Rating
7/22/2020Autolus TherapeuticsSunTrust BanksInitiated Coverage
6/17/2020Autolus TherapeuticsJefferies Financial GroupReiterated Rating
5/11/2021Eiger BioPharmaceuticalsCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellBoost Price Target
1/19/2021Eiger BioPharmaceuticalsWedbushReiterated Rating
9/29/2020Eiger BioPharmaceuticalsLADENBURG THALM/SH SHReiterated Rating
12/16/2019Eiger BioPharmaceuticalsGilford SecuritiesInitiated Coverage
6/26/2019Eiger BioPharmaceuticalsKeyCorpInitiated Coverage
1/28/2019Eiger BioPharmaceuticalsRobert W. BairdInitiated Coverage
12/19/2018Eiger BioPharmaceuticalsBTIG ResearchBoost Price Target
11/10/2020CASI PharmaceuticalsOppenheimerReiterated Rating
1/8/2021Cabaletta BioChardan CapitalReiterated Rating
7/15/2020Cabaletta BioMorgan StanleyBoost Price Target
11/27/2019Cabaletta BioEvercore ISIInitiated Coverage
11/19/2019Cabaletta BioCowenInitiated Coverage
4/11/2021Surface OncologyJonestradingReiterated Rating
(Data available from 5/18/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.